Radical surgery is the standard of care for fit stage I non-small cell lung cancer (NSCLC)
patients. Adjuvant treatment should be offered only as part of an investigation trial. Stage II …

Objectives: The non-small cell lung cancer (NSCLC) meta-analysis suggested a survival
benefit for cisplatin-based chemotherapy when given in addition to surgery, radical …

Lung cancer is the leading cause of cancer death worldwide. Majority of newly diagnosed
lung cancers are non-small cell lung cancer (NSCLC), of which up to half are considered …

The treatments for advanced non-small cell lung cancer (NSCLC) should control both local
and microscopic systemic disease, because the 5-year survival of patients with Stage III …

Background The surgical treatment of stage I and II non-small cell lung cancer (NSCLC)
continues to evolve in the areas of intraoperative lymph node staging (specifically the issue …

Non-small cell lung cancer (NSCLC) constitutes approximately 85% of all lung cancers, with
patients having a poor prognosis. Approximately one third of NSCLC patients present with …

Surgery alone has long been the standard treatment for patients with operable non–small-
cell lung cancer (NSCLC). However, despite complete resection, 5-year survival rates have …

The treatment of lung cancer has changed rapidly over the last few years and now more
than ever a multi-disciplinary approach is vital to patient care. Surgical resection remains the …

The American Joint Committee on Cancer defines stage I non-small cell lung carcinoma
(NSCLC) as consisting of patients with a T1 or T2 primary tumor designation and no …

Background The treatment of stage I and II non-small cell lung cancer (NSCLC) in patients
with good or low surgical risk is primarily surgical resection. However, this area is …